Agilent Technologies, Inc. (NYSE:A) Shares Sold by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. decreased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 27.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,705 shares of the medical research company’s stock after selling 6,185 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Agilent Technologies were worth $2,322,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of A. Carmel Capital Partners LLC lifted its position in Agilent Technologies by 1.2% in the fourth quarter. Carmel Capital Partners LLC now owns 6,709 shares of the medical research company’s stock valued at $933,000 after buying an additional 78 shares during the last quarter. Kepos Capital LP increased its stake in Agilent Technologies by 3.5% in the third quarter. Kepos Capital LP now owns 2,775 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 93 shares during the last quarter. Rosenberg Matthew Hamilton increased its stake in Agilent Technologies by 51.1% in the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 96 shares during the last quarter. Invesco LLC increased its stake in Agilent Technologies by 0.7% in the third quarter. Invesco LLC now owns 15,471 shares of the medical research company’s stock valued at $1,730,000 after purchasing an additional 101 shares during the last quarter. Finally, Balentine LLC increased its stake in Agilent Technologies by 3.4% in the third quarter. Balentine LLC now owns 3,180 shares of the medical research company’s stock valued at $356,000 after purchasing an additional 104 shares during the last quarter.

Agilent Technologies Stock Up 1.0 %

A opened at $137.74 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. The stock has a market capitalization of $40.36 billion, a price-to-earnings ratio of 32.78, a price-to-earnings-growth ratio of 4.13 and a beta of 1.11. The business has a 50-day moving average of $141.59 and a two-hundred day moving average of $130.56. Agilent Technologies, Inc. has a 12 month low of $96.80 and a 12 month high of $151.58.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.22 by $0.07. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The firm’s revenue was down 5.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.37 EPS. On average, research analysts expect that Agilent Technologies, Inc. will post 5.5 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd were paid a $0.236 dividend. This represents a $0.94 annualized dividend and a dividend yield of 0.69%. The ex-dividend date was Monday, April 1st. Agilent Technologies’s dividend payout ratio is currently 22.38%.

Insider Activity

In other news, VP Rodney Gonsalves sold 4,828 shares of Agilent Technologies stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $149.00, for a total value of $719,372.00. Following the transaction, the vice president now directly owns 21,329 shares of the company’s stock, valued at approximately $3,178,021. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total transaction of $239,315.72. Following the transaction, the director now directly owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Rodney Gonsalves sold 4,828 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $149.00, for a total value of $719,372.00. Following the transaction, the vice president now directly owns 21,329 shares in the company, valued at $3,178,021. The disclosure for this sale can be found here. Insiders have sold 61,610 shares of company stock valued at $9,220,333 in the last three months.

Analyst Ratings Changes

Several brokerages have commented on A. Citigroup increased their price target on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Oppenheimer increased their price target on shares of Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. UBS Group increased their price objective on Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and increased their price objective for the company from $145.00 to $163.00 in a report on Friday, April 5th. Finally, Evercore ISI increased their price objective on Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $141.29.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.